Age
Item
male or female subjects, aged 18 - 60
boolean
C0001779 (UMLS CUI [1])
Schizophrenia | Schizophreniform Disorders | Schizoaffective Disorder
Item
subjects must meet a clinical diagnosis of schizophrenia, schizophreniform disorder, or schizoaffective disorder according to dsm-iv
boolean
C0036341 (UMLS CUI [1])
C0036358 (UMLS CUI [2])
C0036337 (UMLS CUI [3])
Illness caused by Substance Use Disorders
Item
subjects' illness must not, in the opinion of the investigator, be caused by substance abuse
boolean
C0221423 (UMLS CUI [1,1])
C0015127 (UMLS CUI [1,2])
C0038586 (UMLS CUI [1,3])
Brief Psychiatric Rating Scale
Item
bprs total score (1 to 7 scale) of greater than or equal to 36 at visit 1
boolean
C0029941 (UMLS CUI [1])
Positive and negative syndrome scale
Item
subjects must have a minimum total score of greater than or equal to 14 on the five items of the panss-ec and at least one individual item score of greater than or equal to 4 using the 1-7 scoring system prior to first dose of double-blind medications
boolean
C0451383 (UMLS CUI [1])
Antipsychotic Agents | Benzodiazepines
Item
treatment with antipsychotics or benzodiazepines within 4 hours prior to the first study drug administration
boolean
C0040615 (UMLS CUI [1])
C0005064 (UMLS CUI [2])
Injection of depot antipsychotic agent
Item
treatment with an injectable depot neuroleptic within 1 injection interval prior to study drug administration
boolean
C2585377 (UMLS CUI [1])
Electroconvulsive Therapy
Item
electroconvulsive therapy (ect) within 1 month (90 days) prior to study entry (visit 1)
boolean
C0013806 (UMLS CUI [1])
Remoxipride
Item
treatment with remoxipride within 6 months (180 days) prior to visit 1
boolean
C0073047 (UMLS CUI [1])
Allergic Reaction Investigational New Drugs
Item
documented history of allergic reaction to study medications
boolean
C1527304 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])